Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1033 participants
INTERVENTIONAL
2001-09-30
2003-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Obese Patients With Type 2 Diabetes
NCT00029848
Obese Patients With or Without Comorbidities (RIO-North America)
NCT00029861
Efficacy and Safety of Rimonabant With or Without Hypocaloric Diet in Obese Patients
NCT00481923
Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)
NCT00386061
High Density Lipoprotein Turnover
NCT00408148
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rimonabant (SR141716)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with untreated dyslipidemia
* Stable weight (variation of less than 5 kg within 3 months prior to screening visit)
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
sanofi-aventis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ICD CSD
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinic of Physicians and Surgeons, LTD
Mesa, Arizona, United States
Arizona Clinical Research Center, Inc.
Tucson, Arizona, United States
Irvine Center for Clinical Research (ICCR)
Irvine, California, United States
Los Angeles Clinical Trials
Los Angeles, California, United States
Apexute
Santa Ana, California, United States
Clinical Research of South Florida
Coral Gables, Florida, United States
Radiant Research
Stuart, Florida, United States
nTouch Research
Peoria, Illinois, United States
nTouch Research
South Bend, Indiana, United States
Bluegrass Clinical Research, Inc.
Louisville, Kentucky, United States
Johns Hopkins Women's Research Core
Lutherville, Maryland, United States
Baystate Medical Center
Springfield, Massachusetts, United States
Twin Cities Clinical Research
Arden Hills, Minnesota, United States
Radiant Research
Edina, Minnesota, United States
Women's Clinic of Lincoln, PC
Lincoln, Nebraska, United States
New Mexico Clinical Research & Osteoporosis Center, Inc.
Albuquerque, New Mexico, United States
Clinical Research Services
Bismarck, North Dakota, United States
University of Cincinnati College of Medicine
Cincinnati, Ohio, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
Clinical Research Division
Newtown, Pennsylvania, United States
Clinical Research Center of Reading, LLC
West Reading, Pennsylvania, United States
Medical University of South Carolina, Division of Clinical Pharmacology
Charleston, South Carolina, United States
Nashville Medical Research Institute
Nashville, Tennessee, United States
Radiant Research
Salt Lake City, Utah, United States
Clinical Research Center of Northern Virginia
Falls Church, Virginia, United States
Hunter Holmes McGuire Medical Center Research Service (151)
Richmond, Virginia, United States
Vancouver Medical Weight Loss Clinic
Vancouver, Washington, United States
Addiction & Psychiatric Medicine Research
Morgantown, West Virginia, United States
Sanofi-aventis Administrative Office
Macquarie Park, , Australia
Sanofi-aventis Administrative Office
Laval, , Canada
Sanofi-aventis Administrative Office
Helsinki, , Finland
Sanofi-aventis Administrative Office
Milan, , Italy
Sanofi-aventis Administrative Office
Barcelona, , Spain
Sanofi-aventis Administrative Office
Bromma, , Sweden
Sanofi-aventis Administrative Office
Geneva, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Despres JP, Golay A, Sjostrom L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005 Nov 17;353(20):2121-34. doi: 10.1056/NEJMoa044537.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EFC4735
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.